IPCALAB - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.8
| Stock Code | IPCALAB | Market Cap | 38,840 Cr. | Current Price | 1,531 ₹ | High / Low | 1,624 ₹ |
| Stock P/E | 38.7 | Book Value | 292 ₹ | Dividend Yield | 0.26 % | ROCE | 17.3 % |
| ROE | 12.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,499 ₹ | DMA 200 | 1,450 ₹ |
| Chg in FII Hold | 0.01 % | Chg in DII Hold | 0.14 % | PAT Qtr | 303 Cr. | PAT Prev Qtr | 305 Cr. |
| RSI | 56.1 | MACD | 8.64 | Volume | 3,67,675 | Avg Vol 1Wk | 2,14,309 |
| Low price | 1,252 ₹ | High price | 1,624 ₹ | PEG Ratio | -30.2 | Debt to equity | 0.11 |
| 52w Index | 75.0 % | Qtr Profit Var | 13.4 % | EPS | 31.7 ₹ | Industry PE | 30.1 |
📊 Chart & Indicators
- Current price (₹1,531) is above DMA 50 (₹1,499) and DMA 200 (₹1,450), confirming bullish momentum.
- RSI at 56.1 indicates healthy strength, not yet overbought.
- MACD at 8.64 shows positive crossover, supporting upward bias.
- Bollinger Bands: price near upper band, suggesting strong momentum but mild risk of pullback.
- Volume (3.67 Lakh) above average (2.14 Lakh), showing strong participation.
🎯 Entry & Exit Zones
- **Entry Zone:** ₹1,510 – ₹1,530 (near DMA 50 support).
- **Exit Zone:** ₹1,600 – ₹1,624 (recent high resistance).
- **Stop-Loss:** Below ₹1,495 (DMA 50 breakdown risk).
📈 Trend Status
- The stock is **trending upward** with bullish bias.
- Sustaining above ₹1,530 could lead to further upside toward ₹1,600+.
✅ Positive
- Strong ROCE (17.3%) and ROE (12.4%).
- EPS at ₹31.7 with consistent growth.
- Low debt-to-equity ratio (0.11).
- Price trading above both 50 DMA and 200 DMA.
- Institutional holdings stable with slight increases in FII (+0.01%) and DII (+0.14%).
⚠️ Limitation
- PEG ratio (-30.2) indicates poor earnings growth outlook.
- Dividend yield modest at 0.26%.
- Quarterly PAT slightly declined (₹305 Cr. → ₹303 Cr.).
- P/E (38.7) higher than industry average (30.1), suggesting overvaluation.
📉 Company Negative News
- Flat quarterly PAT performance.
- Overvaluation concerns with high P/E and weak PEG ratio.
📈 Company Positive News
- Strong fundamentals with low leverage and healthy returns.
- Stable institutional holdings.
- Technical indicators (MACD, RSI, DMA crossover) showing bullish strength.
🏭 Industry
- Industry PE at 30.1 vs IPCALAB PE at 38.7, indicating premium valuation.
- Pharma sector remains resilient with steady demand and defensive positioning.
🔎 Conclusion
IPCALAB is showing **bullish short-term signals** with price above both 50 DMA and 200 DMA, supported by MACD and RSI strength. Fundamentals remain stable, though valuation is stretched and earnings growth outlook is weak. Entry near ₹1,510–₹1,530 is favorable, with exits around ₹1,600–₹1,624. Trend remains bullish short-term but requires stronger earnings momentum for sustained medium-term upside.
Would you like me to also prepare a peer benchmarking overlay comparing IPCALAB with other pharma stocks (like Sun Pharma, Cipla, and Dr. Reddy’s) to highlight relative strength and valuation?